The anti-interleukin-6 (IL-6) chimeric monoclonal antibody siltuximab is the first drug to be approved for the treatment of multicentric Castleman’s disease (MCD) in the US and European union (EU), having gained approval under the FDA priority review program in the US and from an accelerated assessment and recommendation by the Committee for Medicinal Products for Human Use (CHMP) in the EU. Development of the drug is continuing in smoldering multiple myeloma. This article summarizes the milestones in the development of siltuximab leading to this first approval for MCD.
KeywordsEuropean Union Multiple Myeloma Bortezomib Tocilizumab CHMP
The preparation of this report was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. A. Markham is a contracted employee of Adis, Springer SBM. T. Patel is a salaried employee of Adis, Springer SBM.
- 4.Chugai Pharmaceutical. Chugai Pharmaceutical’s innovative Castleman’s disease drug ACTEMRA now available in Japan (media release), 14 June 2005. www.japancorp.net.
- 5.US Food and Drug Administration. FDA approves Sylvant for rare Castleman’s disease (media release), 23 April 2014. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm394522.htm.
- 6.Janssen Biotech. SYLVANT(Tm) (siltuximab) Receives FDA Approval to treat multicentric Castleman’s disease (MCD): first treatment approved for patients with rare blood disorder (media release), 23 April 2014. http://www.janssenbiotech.com.
- 7.US Food and Drug Administration. SYLVANT prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125496s000lbl.pdf. Accessed 15 May 2014.
- 8.European Commission. Community register of medicinal products for human use: SYLANT authorisation 2014. http://ec.europa.eu/health/documents/community-register/html/h928.htm. Accessed 10 Jun 2014.
- 9.Committee for Medicinal Products for Human Use (CHMP) EMA. Summary of opinion (initial authorisation) Sylvant Siltuximab. 2014. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2014/03/WC500163529.pdf.
- 16.Coward J, Kulbe H, Leader D, et al. Interleukin-6 as a therapeutic target in advanced ovarian cancer [abstract no. 5331]. In: 101st Annual Meeting of the American Association for Cancer Research; 17-21 Apr 2010; Washington, DC.Google Scholar
- 19.Xie L, Li LY, Kurzrock R, et al. Population pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody, siltuximab (CNTO 328), in patients with B-cell non-Hodgkin’s lymphoma, multiple myeloma, or Castleman’s disease. In: Blood Conference: 54th Annual Meeting of the American Society of Hematology, ASH. 2012;120(21).Google Scholar
- 21.Angevin E, Elez E, Cohen SJ, et al. Phase I/II, two-part, open-label, multiple-dose, dose-escalation study of siltuximab in patients with solid tumors [abstract no. 2583]. J Clin Oncol Conf. 2012;30(15 suppl).Google Scholar
- 22.Wong RS, Casper C, Munshi N, et al. A multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with multicentric Castleman’s disease. In: Blood Conference: 55th Annual Meeting of the American Society of Hematology, ASH. 2013;122(21).Google Scholar
- 23.Van Rhee F, Casper C, Voorhees PM, et al. An open-label, phase 2, multicenter study of the safety of long-term treatment with siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman’s disease. In: Blood Conference: 55th Annual Meeting of the American Society of Hematology, ASH. 2013;122(21).Google Scholar
- 24.Kirk M, Kurzrock R, Van Rhee F, et al. Siltuximab reverses muscle wasting in patients with multicentric Castleman’s disease. In: Blood Conference: 55th Annual Meeting of the American Society of Hematology, ASH. 2013;122(21).Google Scholar
- 25.San Miguel J, Blade J, Shpilberg O, et al. Randomized, open label, phase 2 study of siltuximab (an anti IL 6 mAb) and bortezomib melphalan prednisone versus bortezomib-melphalan-prednisone in patients with newly diagnosed multiple myeloma. Blood. 2014. doi: 10.1182/blood-2013-12-546374.
- 26.Orlowski RZ, Gercheva L, Williams C, et al. Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/ refractory multiple myeloma [abstract no. 8018]. J Clin Oncol 2012;30(Suppl).Google Scholar